Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.93% | -64.73% | -190.49% | -265.08% | 143.42% |
| Total Depreciation and Amortization | 7.70% | 9.49% | 11.27% | 12.31% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -79.23% | -60.60% | -38.69% |
| Total Other Non-Cash Items | 610.82% | 760.66% | 388.36% | 256.58% | -310.06% |
| Change in Net Operating Assets | -419.85% | 107.70% | 166.80% | 141.80% | 78.37% |
| Cash from Operations | -109.75% | 758.12% | 210.02% | 72.41% | 126.47% |
| Capital Expenditure | 33.96% | -11.58% | 0.45% | -102.90% | -131.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 126.77% | 135.34% | 297.04% | -227.59% | -223.79% |
| Cash from Investing | 120.48% | 125.26% | 268.18% | -243.13% | -238.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -16.59% | -85.30% | -100.00% | -100.00% | -53.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -212.32% | -168.09% | -171.05% | -100.00% | -53.57% |
| Foreign Exchange rate Adjustments | 130.38% | 121.93% | 50.44% | 39.42% | 26.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.02% | -159.39% | -27.74% | -169.44% | -136.08% |